文献速递心血管乳腺US

应变引导管理对潜在心脏毒性癌症治疗的心脏保护:SUCCOUR试验3年结果

Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial.
PubMed 文献 · JACC Cardiovasc Imaging · 2022-11-16

SUCCOUR国际多中心随机试验纳入331例接受蒽环类化疗且伴心衰危险因素的患者,随机分入GLS引导或EF引导的心脏保护策略。3年随访时两组3D EF变化无差异(P=0.99),GLS引导组心脏保护启动率更高(31% vs 14.6%,P=0.03),但癌症治疗相关心功能障碍发生率无统计学差异。

要点

  • GLS引导组心脏保护启动率显著高于EF引导组(31% vs 14.6%,P=0.03)。
  • 3年时两组3D EF变化无差异(-0.02% vs -0.03%,P=0.99)。
  • GLS引导未显著降低3年癌症治疗相关心功能障碍发生率(P=0.16)。
英文原文(摘要)· 点击展开

BACKGROUND: Global longitudinal strain (GLS) can predict cancer therapeutics-related cardiac dysfunction and guide initiation of cardioprotection (CPT).

OBJECTIVES: In this study, the authors sought to determine whether echocardiography GLS-guided CPT provides less cardiac dysfunction in survivors of potentially cardiotoxic chemotherapy, compared with usual care at 3 years.

METHODS: In this international multicenter prospective randomized controlled trial, patients were enrolled from 28 international sites. All patients treated with anthracyclines with another risk factor for heart failure were randomly allocated to GLS-guided (>12% relative reduction in GLS) or ejection fraction (EF)-guided (>10% absolute reduction of EF to <55%) CPT. The primary end point was the change in 3-dimensional (3D) EF (ΔEF) from baseline to 3 years.

RESULTS: Among 331 patients enrolled, 255 (77%, age 54 ± 12 years, 95% women) completed 3-year follow-up (123 in the EF-guided group and 132 in the GLS-guided group). Most had breast cancer (n = 236; 93%), and anthracycline followed by trastuzumab was the most common chemotherapy regimen (84%). Although 67 (26%) had hypertension and 32 (13%) had diabetes mellitus, left ventricular function was normal at baseline (EF: 59% ± 6%, GLS: 20.7% ± 2.3%). CPT was administered in 18 patients (14.6%) in the EF-guided group and 41 (31%) in the GLS-guided group (P = 0.03). Most patients showed recovery in EF and GLS after chemotherapy; 3-year ΔEF was -0.03% ± 7.9% in the EF-guided group and -0.02% ± 6.5% in the GLS-guided (P = 0.99) group; respective 3-year EFs were 58% ± 6% and 59% ± 5% (P = 0.06). At 3 years, 17 patients (5%) had cancer therapeutics-related cardiac dysfunction (11 in the EF-guided group and 6 in the GLS guided group; P = 0.16); 1 patient in each group was admitted for heart failure.

CONCLUSIONS: Among patients taking potentially cardiotoxic chemotherapy for cancer, the 3-year data showed improvement of LV dysfunction compared with 1 year, with no difference in ΔEF between GLS- and EF-guided CPT. (Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes [SUCCOUR]; ACTRN12614000341628).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Negishi, Thavendiranathan, Penicka, et al. Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial. JACC Cardiovasc Imaging. 2022. PMID: 36435732. doi:10.1016/j.jcmg.2022.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。